• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 3. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 4. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

Introduction to Tert-butyl N-[(1R,2S)-2-hydroxycyclohexyl]carbamate (CAS No. 291533-28-3)

Tert-butyl N-[(1R,2S)-2-hydroxycyclohexyl]carbamate, identified by its Chemical Abstracts Service (CAS) number 291533-28-3, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and drug development. This compound belongs to the class of carbamates, which are widely recognized for their versatility in medicinal applications due to their ability to act as intermediates in the synthesis of bioactive molecules. The unique structural features of Tert-butyl N-[(1R,2S)-2-hydroxycyclohexyl]carbamate, particularly its chiral center and hydroxyl group, make it a promising candidate for further exploration in the development of novel therapeutic agents.

The stereochemistry of (1R,2S)-2-hydroxycyclohexyl moiety is a critical aspect of this compound's molecular architecture. The presence of a specific absolute configuration at the 1 and 2 positions of the cyclohexane ring imparts unique physicochemical properties that can influence its biological activity. This chirality is often exploited in drug design to enhance selectivity and reduce off-target effects, which are crucial considerations in modern medicinal chemistry. The tert-butyl carbamate group not only serves as a protecting group but also contributes to the overall solubility and stability of the molecule, making it suitable for various pharmaceutical formulations.

In recent years, there has been growing interest in the development of carbamate-based drugs due to their favorable pharmacokinetic profiles and reduced toxicity compared to some traditional small-molecule inhibitors. Studies have demonstrated that carbamates can exhibit potent binding interactions with biological targets, making them valuable scaffolds for drug discovery. The hydroxyl group in (1R,2S)-2-hydroxycyclohexyl further enhances the compound's potential by allowing hydrogen bonding interactions, which are essential for maintaining binding affinity and specificity.

Current research in the field of chiral carbamates has highlighted their role in modulating enzyme activity and receptor binding. For instance, studies have shown that derivatives of carbamates can selectively inhibit certain enzymes by occupying specific binding pockets. This selectivity is particularly important in therapeutic contexts where off-target effects can lead to adverse reactions. The structural flexibility of Tert-butyl N-[(1R,2S)-2-hydroxycyclohexyl]carbamate allows for modifications that can fine-tune its biological activity, making it a versatile building block for medicinal chemists.

The synthesis of Tert-butyl N-[(1R,2S)-2-hydroxycyclohexyl]carbamate involves multi-step organic transformations that require precise control over reaction conditions to ensure high yield and enantiomeric purity. The preparation typically begins with the functionalization of cyclohexanol derivatives followed by protection-deprotection strategies to introduce the carbamate moiety. Advanced synthetic techniques such as asymmetric hydrogenation have been employed to achieve the desired stereochemistry efficiently. These synthetic methodologies underscore the compound's complexity and highlight the expertise required for its production.

From a pharmacological perspective, Tert-butyl N-[(1R,2S)-2-hydroxycyclohexyl]carbamate has shown promise in preclinical studies as a potential lead compound for treating various diseases. Its ability to interact with biological targets in a selective manner suggests applications in areas such as inflammation modulation and metabolic disorders. Additionally, its stability under physiological conditions makes it suitable for formulation into oral or injectable medications. Further investigation into its pharmacodynamics and pharmacokinetics will be essential to fully elucidate its therapeutic potential.

The chemical properties of this compound also make it an interesting subject for computational studies. Molecular modeling techniques have been used to predict how Tert-butyl N-[(1R,2S)-2-hydroxycyclohexyl]carbamate interacts with biological targets at the atomic level. These simulations help researchers understand the binding mechanism and identify key residues involved in drug-receptor interactions. Such insights are invaluable for optimizing lead compounds and designing next-generation drugs with improved efficacy and safety profiles.

In conclusion, Tert-butyl N-[(1R,2S)-2-hydroxycyclohexyl]carbamate (CAS No. 291533-28-3) represents a significant advancement in pharmaceutical chemistry due to its unique structural features and promising biological activities. Its stereochemistry, functional groups, and synthetic accessibility make it a valuable tool for drug discovery efforts aimed at addressing unmet medical needs. As research continues to uncover new applications for this compound, it is likely to play an increasingly important role in the development of innovative therapeutic strategies.

• 296778-53-5(Carbamic acid, [(1R,2S)-2-hydroxycyclohexyl]-, 1,1-dimethylethyl ester, rel-)
• 511268-25-0(Carbamic acid, N-[(1S)-1-(2-amino-1-hydroxyethyl)pentyl]-, 1,1-dimethylethyl ester)
• 121282-70-0(tert-butyl N-[trans-2-hydroxycyclohexyl]carbamate)
• 477584-30-8(tert-butyl N-(2-hydroxycyclohexyl)carbamate)
• 145166-06-9(tert-butyl N-[(1S,2S)-2-hydroxycyclohexyl]carbamate)
• 214679-17-1(tert-butyl N-[(1S,2R)-2-hydroxycyclohexyl]carbamate)
• 145106-43-0(tert-butyl N-[(1S,2S)-2-hydroxycyclopentyl]carbamate)
• 155837-16-4(tert-butyl N-[cis-2-hydroxycyclopentyl]carbamate)
• 155975-19-2(tert-butyl N-[(1R,2R)-2-hydroxycyclohexyl]carbamate)
• 599207-03-1(Carbamic acid, [(1S)-1-[(1R)-1-hydroxyethyl]butyl]-, 1,1-dimethylethyl ester)